Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | hypothetical protein, conserved | 0.0197 | 0 | 0.5 |
Schistosoma mansoni | chromatin regulatory protein sir2 | 0.1024 | 1 | 1 |
Echinococcus multilocularis | NAD dependent deacetylase sirtuin 1 | 0.055 | 0.4271 | 0.4271 |
Leishmania major | silent information regulator 2, putative | 0.1024 | 1 | 1 |
Schistosoma mansoni | chromatin regulatory protein sir2 | 0.1024 | 1 | 1 |
Trichomonas vaginalis | chromatin regulatory protein sir2, putative | 0.1024 | 1 | 1 |
Trichomonas vaginalis | chromatin regulatory protein sir2, putative | 0.055 | 0.4271 | 0.4271 |
Trichomonas vaginalis | chromatin regulatory protein sir2, putative | 0.1024 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0354 | 0.1894 | 0.1894 |
Echinococcus granulosus | NAD dependent deacetylase sirtuin 1 | 0.055 | 0.4271 | 0.4271 |
Mycobacterium tuberculosis | Transcriptional regulatory protein | 0.0197 | 0 | 0.5 |
Entamoeba histolytica | Sir2 family transcriptional regulator, putative | 0.1024 | 1 | 1 |
Trypanosoma brucei | Silent information regulator 2 related protein 1 | 0.1024 | 1 | 1 |
Mycobacterium ulcerans | Sir2-like regulatory protein | 0.0197 | 0 | 0.5 |
Trichomonas vaginalis | chromatin regulatory protein sir2, putative | 0.055 | 0.4271 | 0.4271 |
Trichomonas vaginalis | chromatin regulatory protein sir2, putative | 0.055 | 0.4271 | 0.4271 |
Echinococcus multilocularis | NAD dependent deacetylase sirtuin 3 | 0.1024 | 1 | 1 |
Giardia lamblia | NAD-dependent histone deacetylase Sir2 | 0.055 | 0.4271 | 0.4271 |
Plasmodium falciparum | transcriptional regulatory protein sir2a | 0.0197 | 0 | 0.5 |
Schistosoma mansoni | chromatin regulatory protein sir2 | 0.1024 | 1 | 1 |
Trypanosoma cruzi | Silent information regulator 2 related protein 1 | 0.1024 | 1 | 1 |
Entamoeba histolytica | Sir2 family transcriptional regulator, putative | 0.1024 | 1 | 1 |
Schistosoma mansoni | chromatin regulatory protein sir2 | 0.055 | 0.4271 | 0.4271 |
Loa Loa (eye worm) | hypothetical protein | 0.055 | 0.4271 | 0.4271 |
Toxoplasma gondii | histone deacetylase SIR2-like | 0.0197 | 0 | 0.5 |
Echinococcus granulosus | chromatin regulatory protein sir2 | 0.1024 | 1 | 1 |
Echinococcus multilocularis | chromatin regulatory protein sir2 | 0.1024 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.1024 | 1 | 1 |
Plasmodium vivax | NAD-dependent deacetylase, putative | 0.0197 | 0 | 0.5 |
Trichomonas vaginalis | chromatin regulatory protein sir2, putative | 0.055 | 0.4271 | 0.4271 |
Trypanosoma cruzi | Silent information regulator 2 related protein 1 | 0.1024 | 1 | 1 |
Brugia malayi | NAD-dependent deacetylase SIRT1 | 0.055 | 0.4271 | 0.4271 |
Echinococcus granulosus | NAD dependent deacetylase sirtuin 3 | 0.1024 | 1 | 1 |
Toxoplasma gondii | histone deacetylase SIR2 | 0.0197 | 0 | 0.5 |
Loa Loa (eye worm) | transcriptional regulator | 0.1024 | 1 | 1 |
Plasmodium falciparum | transcriptional regulatory protein sir2b | 0.0197 | 0 | 0.5 |
Mycobacterium ulcerans | NAD-dependent deacetylase | 0.0197 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS for Inhibitors of Glutaminase (GLS). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | 56.2341 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.